That makes sense, they have a foothold and strong presence in a very large market. I guess there are lots of different types and ways to make deals, and/or multiple licensing deals, if/when things turn out well. 

I'm longggg on RVX, but "short term" long (getting older) haha, so I am honestly desiring a buy out and one clean transaction rather than a ramp up to market. But maybe things could go in stages also, like what if Hepalink could begin to address the Asian markets sooner than the FDA allows in the U.S.?

... don't know the answers or even the possibilities, just things that make you go "hmmmm ..."

Does anyone else know about the Asian governing bodies and possibility of Hepalink manufacturing & marketing apabetalone in Asia, based on BoM data, while we continue the path through the FDA? ... seems like this has been discussed before, just can't remember?